$86.4 Million is the total value of RiverVest Venture Management LLC's 6 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MIRM | Mirum Pharmaceuticals, Inc. | $38,939,254 | +23.2% | 1,621,118 | 0.0% | 45.05% | +22.2% | |
| ALLK | Allakos, Inc. | $21,751,297 | -47.1% | 4,887,932 | 0.0% | 25.16% | -47.6% | |
| RPHM | Reneo Pharmaceuticals, Inc. | $14,407,136 | +156.7% | 2,409,220 | 0.0% | 16.67% | +154.6% | |
| SPRB | Buy | Spruce Bioscience, Inc. | $6,489,180 | +175.3% | 2,936,281 | +36.7% | 7.51% | +173.0% |
| Xilio Therapeutics, Inc. | $4,569,377 | +17.8% | 1,441,444 | 0.0% | 5.29% | +16.9% | ||
| VAPO | Buy | Vapotherm, Inc. | $278,414 | -75.0% | 423,058 | +2.5% | 0.32% | -75.2% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-04-27
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Allakos, Inc. | 12 | Q3 2023 | 88.4% |
| Spruce Bioscience, Inc. | 12 | Q3 2023 | 16.4% |
| Vapotherm, Inc. | 12 | Q3 2023 | 6.0% |
| Mirum Pharmaceuticals, Inc. | 11 | Q2 2023 | 54.9% |
| Reneo Pharmaceuticals, Inc. Fund 4 | 10 | Q3 2023 | 47.7% |
| Xilio Therapeutics, Inc. | 8 | Q3 2023 | 16.5% |
| Otonomy, Inc. | 1 | Q4 2020 | 0.4% |
View RiverVest Venture Management LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-12 |
| 13F-HR | 2023-10-30 |
| 13F-HR | 2023-08-07 |
| 13F-HR | 2023-04-27 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-10 |
| 13F-HR | 2022-05-02 |
| 13F-HR | 2022-02-07 |
| 13F-HR | 2021-11-12 |
View RiverVest Venture Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.